Bording A, Nymark K, Smidt E
Department of Animal Science and Animal Health, Royal Veterinary and Agricultural University, Copenhagen, Denmark.
Acta Vet Scand. 1994;35(2):155-63. doi: 10.1186/BF03548343.
Field trials were carried out testing a new genetically engineered vaccine against Progressive Atrophic Rhinitis. The vaccine contained a non-toxic recombinant derivative of the P. multocida toxin. The experimental vaccine was compared with a commercial vaccine in 4 farms and in 1 farm 2 different dose regimens were applied. A total of 825 sows were included. The primary efficacy variable was a comparison of post mortem evaluation of the degree of conchae atrophy in the 4585 pigs. The pigs were slaughtered at normal slaughter weight. The secondary efficacy variables were serological response and age at slaughter. In all farms the experimental vaccine provided significantly better protection of the progeny than the control vaccine. The serological response in sows was significantly higher in all farms than the response to the control vaccine. The serological response did not differ between farms.
进行了田间试验，测试一种针对进行性萎缩性鼻炎的新型基因工程疫苗。该疫苗含有多杀性巴氏杆菌毒素的无毒重组衍生物。在4个猪场将实验疫苗与一种商业疫苗进行比较，并在1个猪场应用了2种不同的剂量方案。总共纳入了825头母猪。主要疗效变量是对4585头猪的鼻甲萎缩程度进行死后评估的比较。猪在正常屠宰体重时屠宰。次要疗效变量是血清学反应和屠宰时的年龄。在所有猪场中，实验疫苗对后代的保护作用均显著优于对照疫苗。所有猪场中母猪的血清学反应均显著高于对对照疫苗的反应。各猪场之间的血清学反应没有差异。
